Menu
← Oncology Approval Tracker
FDA DECISION ·
Pemfexy + pembrolizumab and platinum
pemetrexed plus pembrolizumab and platinum chemotherapy · Eagle Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Initial combination treatment for metastatic nonsquamous NSCLC without EGFR or ALK genomic aberrations, using Pemfexy with pembrolizumab and platinum chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The action adds a specific first-line combination to the Pemfexy label.
What research teams should watch
Verify EGFR and ALK results and check the exact pemetrexed product in treatment orders.
PRIMARY RECORDS